Aortic Valve Replacement in Bioprosthetic Failure: Insights from The STS National Database (Commentary)
Publication date: Available online 30 September 2019Source: The Annals of Thoracic SurgeryAuthor(s): Marjan Jahangiri
Authors: Kim MC, Kim JH, Cho KH, Sim DS, Hong YJ, Ahn Y, Jeong MH PMID: 32096360 [PubMed - as supplied by publisher]
Patients with low-flow, low-gradient aortic stenosis (LFLG-AS) who don't show improvement in mitral regurgitation following transcatheter aortic-valve replacement (TAVR) face an increased risk of mortality, according to a substudy of a multicenter registry.Reuters Health Information
Surgical repair of concomitant functional moderate tricuspid valve (TV) regurgitation at the time of mitral valve (MV) surgery remains controversial.
We thank Dr Doenst for discussing the role of the in vivo effective orifice area (EOA) in judging the performance of surgical heart valves (SHVs) in relation to the Position Statement of the European Association for Cardio-Thoracic Surgery Society of Thoracic Surgeons American Association for Thoracic Surgery Valve Labelling Task Force.1
Conclusion: Surgical treatment for NVE is associated with considerable mortality. The in-hospital mortality and 5-year survival rates of this study were 13.8% and 77.2%, respectively. Underlying conditions, including hypertension and ESRD, and urgent surgery were independent risk factors for unfavorable outcomes. PMID: 32090051 [PubMed]
Publication date: Available online 24 February 2020Source: Canadian Journal of CardiologyAuthor(s): Harold L. Lazar
Authors: Matsumoto Y, Ayani N, Kuwabara K, Ono J, Yamada K, Narumoto J PMID: 32088585 [PubMed - as supplied by publisher]
Publication date: Available online 24 February 2020Source: The Annals of Thoracic SurgeryAuthor(s): Paul C. Tang, Nadeen Sarsour, Jonathan W. Haft, Matthew A. Romano, Matthew Konerman, Monica Colvin, Todd Koelling, Keith D. Aaronson, Francis D. Pagani
(Osaka University) Researchers at Osaka University succeed in Japan's first beating-heart surgery to repair a mitral valve without using artificial heart lung apparatus. This approach can avoid complications arising from the use of artificial heart lung apparatus, and more favorable and earlier postoperative recovery is expected.
Asymptomatic aortic stenosis (AS) is a challenging disease. Until recently, there was no definitive evidence for early intervention in asymptomatic severe AS, and thus guidelines still incorporate symptom status as a key factor in decision-making.1 Recent prospective data, however, have shown that asymptomatic very severe AS should be treated. Kang et al.2 reported a randomized controlled trial of 145 patients that showed a clear survival benefit for surgical valve replacement in patients with asymptomatic very severe AS (aortic valve area [AVA] ≤ 0.75 cm2 with either peak velocity ≥ 4....